PDS Biotechnology’s (PDSB) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

Other research analysts have also recently issued reports about the company. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. B. Riley dropped their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, November 25th. Finally, Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.67.

PDS Biotechnology Stock Down 7.9 %

PDSB stock opened at $1.81 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. PDS Biotechnology has a 1-year low of $1.53 and a 1-year high of $6.68. The stock has a market capitalization of $67.52 million, a P/E ratio of -1.56 and a beta of 1.85. The business has a fifty day moving average price of $2.64 and a 200-day moving average price of $3.04.

Institutional Trading of PDS Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in shares of PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after purchasing an additional 37,142 shares in the last quarter. XTX Topco Ltd raised its stake in PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after buying an additional 47,528 shares during the last quarter. Vontobel Holding Ltd. grew its stake in shares of PDS Biotechnology by 233.3% during the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after acquiring an additional 28,000 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of PDS Biotechnology during the second quarter valued at about $146,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PDS Biotechnology in the 2nd quarter valued at approximately $115,000. 26.84% of the stock is owned by hedge funds and other institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.